Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand EZH2 activity. [Cut & Run]

ABSTRACT: EZH2 has differential activity in prostate adenocarcinoma and neuroendocrine prostate cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE256219 | GEO | 2024/07/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand DNMT-EZH2 crosstalk. [Cut&Run]

Project description:EZH2-DNMT crosstalk is diverse across prostate adenocarcinoma and neuroendocrine prostate cancer.

2025-11-25 | GSE286954 | GEO

Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand DNMT-EZH2 crosstalk. [RNA-Seq]

Project description:EZH2-DNMT crosstalk is diverse across prostate adenocarcinoma and neuroendocrine prostate cancer.

2025-11-25 | GSE286958 | GEO

Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand EZH2 activity. [Cut & Run]

Project description:Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand EZH2 activity. [Cut & Run]

| PRJNA1078705 | ENA

Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand DNMT-EZH2 crosstalk. [Cut&Run]

Project description:Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand DNMT-EZH2 crosstalk. [Cut&Run]

| PRJNA1210599 | ENA

Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand DNMT-EZH2 crosstalk. [RNA-Seq]

Project description:Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand DNMT-EZH2 crosstalk. [RNA-Seq]

| PRJNA1210603 | ENA

Neuroendocrine prostate cancer models

Project description:Neuroendocrine prostate cancer models

| PRJNA449097 | ENA

DPYSL5 is Highly Expressed in treatment-induced Neuroendocrine Prostate Cancer and Promotes Lineage Plasticity via EZH2/PRC2

Project description:Treatment-induced neuroendocrine prostate cancer (t-NEPC) is a lethal subtype of castration-resistant prostate cancer resistant to androgen receptor (AR) inhibitors. Our study unveils that AR suppresses neuronal development protein dihydropyrimidinase-related protein 5 (DPYSL5), providing a mechanism for neuroendocrine transformation under androgen deprivation therapy. Our unique CRPC-NEPC cohort with 157 patient samples, including 55 t-NEPC patient samples, shows a high expression of DPYSL5 in t-NEPC patients, and that DPYSL5 correlates with neuroendocrine markers and inversely with AR and PSA. DPYSL5 overexpression in prostate cancer cells induces neuron like phenotype, enhances invasion, proliferation, and upregulates stemness and neuroendocrine related markers. Mechanistically, DPYSL5 promotes prostate cancer cell plasticity via EZH2-mediated PRC2 activation. Depletion of DPYSL5 halts proliferation, induces G1 phase cell cycle arrest, reverses neuroendocrine phenotype and upregulates luminal genes. In conclusion, DPYSL5 plays a critical role in regulating prostate cancer cell plasticity, and we propose the AR/DPYSL5/EZH2/PRC2 axis as a novel driver of t-NEPC progression.

2024-01-02 | GSE151433 | GEO

Epigenomic profiling of neuroendocrine prostate cancer and prostate adenocarcinoma xenografts

Project description:We profiled the epigenomes of neuroendocrine prostate cancer and prostate adenocarcinoma patient-derived xenografts using ChIP-seq for transcription factors and histone modifications.

2020-11-22 | GSE161948 | GEO

EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer [RNAseq]

Project description:Advanced prostate cancer (PrCa) remains a leading cause of cancer-related death among men because nearly all patients progress on standard therapy that targets androgen receptor (AR) signaling. An important mechanism driving therapeutic resistance is lineage plasticity, the ability of PrCa cells to reprogram into AR independent lineage variants like neuroendocrine (NE) PrCa. The histone methyltransferase EZH2 has been implicated in PrCa lineage plasticity and EZH2 inhibitors are being evaluated clinically for the treatment of PrCa. Here we test how Ezh2 impacts the evolution of PrCa lineage plasticity using genetically engineered mice and human patient data. Ezh2 deficiency in mice diversifies the evolution of PrCa lineage variants, including a newly discovered variant with high expression of neurofilament genes. Analogous PrCa lineage variants are detectable in human specimens where they similarly correlate with EZH2 expression. Lineage variant diversification is associated with activation of transcription factor programs and AR cistrome reprogramming that is normally repressed by Ezh2. These findings advance the understanding of PrCa lineage plasticity and have implications for targeting EZH2 as a PrCa therapy.

2025-10-28 | GSE297143 | GEO